ERBB2 and neoplasm: These together resulted in prolonged blood circulation andenhanced accumulation of MSNA-PS to the HER2 expressing tumor tissue.This study serves as a technical demonstration of the applicabilityof MSNAs to site-specific radiolabeling and in vivo tracing providing also a promising benchmark for targeted i.v.-deliveryof [60]fullerene-based DNA-nanomaterials, integrated with tissue-targetingsmall molecular ligands,57−59 aptamers,60,61 and antibodies.62